financetom
Technology
financetom
/
Technology
/
Applied Materials may postpone or cancel $4 billion California R&D facility, SF Chronicle reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Applied Materials may postpone or cancel $4 billion California R&D facility, SF Chronicle reports
Apr 8, 2024 4:16 PM

(Reuters) - Applied Materials ( AMAT ), the largest maker of semiconductor equipment in the U.S., may postpone or abandon its plans to build a $4 billion research and development facility in Silicon Valley due to a lack of government funding, the San Francisco Chronicle reported on Monday citing sources familiar with the matter.

The Biden administration said last month it would scrap plans to fund the program from the $52.7 billion Chips and Science Act due to "overwhelming demand" for funding awards to subsidize chip production.

Applied Materials ( AMAT ) did not immediately respond to a Reuters request for comment.

President Joe Biden had signed the bill in August 2022 amid a global shortage of chips, in a bid to bolster U.S. competitiveness with China in science and technology.

The measure aimed to subsidize U.S. chip manufacturing and expand research funding to address a recurrent shortfall that had harmed a variety of sectors, from cars and weaponry to washing machines and video games.

Applied Materials ( AMAT ), a strong candidate for a research award from the program, announced its plans for the California research center in May 2023 to speed up advances in semiconductor manufacturing.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
Oct 21, 2025
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics ( SION ), Inc. , a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the...
Lightbridge to Hold Business Update & Third Quarter 2025 Earnings Conference Call on Thursday, November 6 at 4 p.m. ET
Lightbridge to Hold Business Update & Third Quarter 2025 Earnings Conference Call on Thursday, November 6 at 4 p.m. ET
Oct 21, 2025
RESTON, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Lightbridge Corporation ( LTBR ) (“Lightbridge” or the “Company”) , an advanced nuclear fuel technology company, will announce its financial results for the third quarter of fiscal year 2025 on Wednesday, November 5, after the market closes. Lightbridge ( LTBR ) will host a conference call on Thursday, November 6, at 4:00...
Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings
Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings
Oct 21, 2025
The investment enhances German facility to deliver more flexible and scalable drug delivery solutions PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced a significant expansion of its drug delivery system manufacturing capacity, further strengthening its global footprint to...
European third-quarter corporate outlook worsens slightly
European third-quarter corporate outlook worsens slightly
Oct 21, 2025
By Javi West Larrañaga and Marleen Kaesebier Oct 21 (Reuters) - The outlook for European corporate health has slightly worsened, the latest earnings forecasts showed on Tuesday. European companies are expected to report an increase of 0.2% in third-quarter earnings, on average, according to LSEG I/B/E/S data, below the 0.5% growth analysts were expecting a week ago. That would be...
Copyright 2023-2026 - www.financetom.com All Rights Reserved